Kangmei Pharmaceutical Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Kangmei Pharmaceutical.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	19.3%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

Subdued Growth No Barrier To Kangmei Pharmaceutical Co., Ltd. (SHSE:600518) With Shares Advancing 35%

Nov 08

We Think Kangmei Pharmaceutical's (SHSE:600518) Robust Earnings Are Conservative

Nov 06

Kangmei Pharmaceutical's (SHSE:600518) Performance Is Even Better Than Its Earnings Suggest

May 06

Kangmei Pharmaceutical Co., Ltd.'s (SHSE:600518) Price Is Out Of Tune With Revenues

Apr 10

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Kangmei Pharmaceutical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SHSE:600518 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
9/30/2024	5,213	256	-503	-414	N/A
6/30/2024	4,971	244	-534	-446	N/A
3/31/2024	4,931	160	-533	-447	N/A
12/31/2023	4,874	103	-417	-318	N/A
9/30/2023	4,992	-1,950	-749	-666	N/A
6/30/2023	4,778	-2,618	-705	-623	N/A
3/31/2023	4,390	-2,627	-829	-754	N/A
12/31/2022	4,180	-2,688	-798	-750	N/A
9/30/2022	3,788	8,057	-318	-231	N/A
6/30/2022	3,862	8,652	-366	-261	N/A
3/31/2022	3,999	8,402	-183	-75	N/A
12/31/2021	4,153	7,918	43	214	N/A
9/30/2021	4,526	-29,738	41	255	N/A
6/30/2021	4,965	-30,591	538	818	N/A
3/31/2021	5,330	-31,383	596	918	N/A
12/31/2020	5,412	-31,085	730	1,031	N/A
9/30/2020	5,070	-7,290	168	474	N/A
6/30/2020	5,830	-6,395	745	1,057	N/A
3/31/2020	7,714	-5,248	2,078	2,411	N/A
12/31/2019	11,446	-4,886	2,409	2,882	N/A
9/30/2019	12,918	-281	7,588	8,237	N/A
6/30/2019	15,590	-29	4,778	7,000	N/A
3/31/2019	19,365	942	-5,037	-898	N/A
12/31/2018	17,065	374	-4,288	306	N/A
9/30/2018	12,559	-312	-16,960	-11,004	N/A
6/30/2018	13,924	487	N/A	-10,403	N/A
3/31/2018	15,317	1,341	N/A	-7,809	N/A
12/31/2017	17,579	2,150	N/A	-4,840	N/A
9/30/2017	24,701	3,900	N/A	2,467	N/A
6/30/2017	23,701	3,726	N/A	2,564	N/A
3/31/2017	22,911	3,419	N/A	2,484	N/A
12/31/2016	21,642	3,340	N/A	1,603	N/A
9/30/2016	21,067	3,241	N/A	557	N/A
6/30/2016	20,205	3,090	N/A	374	N/A
3/31/2016	18,950	2,928	N/A	88	N/A
12/31/2015	18,067	2,757	N/A	509	N/A
9/30/2015	17,827	2,895	N/A	64	N/A
6/30/2015	17,252	2,692	N/A	83	N/A
3/31/2015	16,755	2,513	N/A	1,545	N/A
12/31/2014	15,949	2,286	N/A	1,132	N/A
9/30/2014	15,459	1,991	N/A	2,021	N/A
6/30/2014	15,015	1,962	N/A	2,040	N/A
3/31/2014	14,233	1,913	N/A	1,558	N/A
12/31/2013	13,359	1,880	N/A	1,674	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 600518's forecast earnings growth is above the savings rate (2.8%).

Earnings vs Market: Insufficient data to determine if 600518's earnings are forecast to grow faster than the CN market

High Growth Earnings: Insufficient data to determine if 600518's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 600518's revenue is forecast to grow faster than the CN market.

High Growth Revenue: Insufficient data to determine if 600518's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 600518's Return on Equity is forecast to be high in 3 years time

Kangmei Pharmaceutical Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Subdued Growth No Barrier To Kangmei Pharmaceutical Co., Ltd. (SHSE:600518) With Shares Advancing 35%

We Think Kangmei Pharmaceutical's (SHSE:600518) Robust Earnings Are Conservative

Third quarter 2024 earnings released

Is Kangmei Pharmaceutical (SHSE:600518) A Risky Investment?

Kangmei Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Second quarter 2024 earnings released: EPS: CN¥0 (vs CN¥0.005 loss in 2Q 2023)

What Kangmei Pharmaceutical Co., Ltd.'s (SHSE:600518) P/S Is Not Telling You

Kangmei Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024

We Think Kangmei Pharmaceutical (SHSE:600518) Can Stay On Top Of Its Debt

Kangmei Pharmaceutical's (SHSE:600518) Performance Is Even Better Than Its Earnings Suggest

Full year 2023 earnings released: EPS: CN¥0.01 (vs CN¥0.19 loss in FY 2022)

Kangmei Pharmaceutical Co., Ltd., Annual General Meeting, May 08, 2024

Kangmei Pharmaceutical Co., Ltd.'s (SHSE:600518) Price Is Out Of Tune With Revenues

Kangmei Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Kangmei Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 13, 2024

New major risk - Financial position

High number of new and inexperienced directors

Kangmei Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Oct 28, 2023

Kangmei Pharmaceutical Co., Ltd. to Report Q2, 2023 Results on Aug 19, 2023

First quarter 2023 earnings released: CN¥0.004 loss per share (vs CN¥0.008 loss in 1Q 2022)

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: CN¥0.051 loss per share (vs CN¥0.019 loss in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: CN¥0.006 loss per share (vs CN¥0.067 loss in 2Q 2021)

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Full year 2020 earnings released: CN¥5.62 loss per share (vs CN¥0.99 loss in FY 2019)

Kangmei Pharmaceutical Co., Ltd. Appoints Zhou Yunfeng as Secretary to Directorate

New 90-day low: CN¥2.34

New 90-day low: CN¥2.63

New 90-day low: CN¥2.89

Third quarter earnings released

Kangmei Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 30, 2020

Kangmei Pharmaceutical Co., Ltd. Approves Appointment of Gong Guibo as Deputy General Manager

New 90-day high - CN¥3.26

Kangmei Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies